Literature DB >> 6787058

Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

D C Rijken, D Collen.   

Abstract

The plasminogen activator secreted by a cultured human melanoma cell line was purified and compared with urokinase and with tissue plasminogen activator from human uterus. The purification procedure consisted of chromatography on zinc chelate-agarose, concanavalin A-agarose, and Sephadex G-150 in the presence of 0.01% (v/v) Tween 80. The purified material was obtained from the culture medium with a yield of 46% and a purification factor of 263. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed one main band with a molecular weight of about 72,000, and in the presence of reducing agents, two bands of 33,000 and 39,000. Addition of the protease inhibitor Aprotinin to the culture media and column buffers yielded a one-chain plasminogen activator with a molecular weight of about 72,000. One molecule of activator reacted with about one molecular of [3H]diisopropylfluorophosphate. The melanoma plasminogen activator and the uterine tissue plasminogen activator appeared to be very similar on dodecyl sulfate-polyacrylamide gel electrophoresis, amino acid analysis, and amidolytic properties. Both activators bound to fibrin clots, while urokinase did not. In immunodiffusion, as well as in quenching experiments of the fibrinolytic activities, the melanoma plasminogen activator appeared to be immunologically identical with the uterine tissue plasminogen activator, but unrelated to urokinase. All these findings indicate that the plasminogen activator secreted by human melanoma cells in culture is very similar to, or identical with, the plasminogen activator found in normal tissue, but different from urokinase.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6787058

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  98 in total

1.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.

Authors:  M S Stack; S Gately; L M Bafetti; J J Enghild; G A Soff
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  Effector-assisted refolding of recombinant tissue-plasminogen activator produced in Escherichia coli.

Authors:  H Grunfeld; A Patel; A Shatzman; A H Nishikawa
Journal:  Appl Biochem Biotechnol       Date:  1992-05       Impact factor: 2.926

3.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

Review 4.  Use of plasminogen activators in venous thrombosis.

Authors:  J Hirsh; A G Turpie
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

5.  Blasts from the past.

Authors:  Paul A Insel; Stuart Kornfeld; Philip W Majerus; Andrew R Marks; Paul A Marks; Arnold S Relman; Bruce F Scharschmidt; Thomas P Stossel; Ajit P Varki; Stephen J Weiss; Jean D Wilson
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

6.  Deposition of extracellular matrix along the pathways of migrating fibroblasts.

Authors:  W Halfter; D Liverani; M Vigny; D Monard
Journal:  Cell Tissue Res       Date:  1990-12       Impact factor: 5.249

7.  [Arrhythmia as an indicator for reperfusion following acute myocardial infarct?].

Authors:  K Langes; W Bleifeld; D G Mathey; K H Kuck
Journal:  Klin Wochenschr       Date:  1989-12-04

8.  Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells.

Authors:  R J Kaufman; L C Wasley; A J Spiliotes; S D Gossels; S A Latt; G R Larsen; R M Kay
Journal:  Mol Cell Biol       Date:  1985-07       Impact factor: 4.272

9.  Fibrinolysis in cornea and conjunctiva: evidence of two types of activators.

Authors:  E Lantz; M Pandolfi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

Review 10.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.